A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/517 (2006.01) A61K 31/47 (2006.01) A61K 31/519 (2006.01) A61P 13/08 (2006.01)
Patent
CA 2483590
The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and / or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia / prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), optionally in combination with known compounds for the treatment of benign prostatic hyperplasia / prostatic hypertrophy, as well as associated pharmaceutical compositions.
La présente invention concerne l'utilisation de certains antagonistes du récepteur EGF dans la production d'un médicament destiné à la prévention et/ou au traitement de l'hyperplasie et/ou hypertrophie bénigne de la prostate, une méthode de traitement ou de prévention de l'hyperplasie/hypertrophie bénigne de la prostate, qui consiste à administrer un antagoniste du récepteur EGF des groupes (A), (B) ou (C), éventuellement en combinaison avec des composés connus destinés au traitement de l'hyperplasie/hypertrophie bénigne de la prostate, ainsi que des compositions pharmaceutiques correspondantes.
Colbatzky Florian
Platz Stefan
Singer Thomas
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Fetherstonhaugh & Co.
LandOfFree
Use of inhibitors of egfr-mediated signal transduction for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of inhibitors of egfr-mediated signal transduction for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of inhibitors of egfr-mediated signal transduction for... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1599231